CSF parameters associated with early MRI activity in patients with MS.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wolters Kluwer Health/Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101636388 Publication Model: eCollection Cited Medium: Internet ISSN: 2332-7812 (Electronic) Linking ISSN: 23327812 NLM ISO Abbreviation: Neurol Neuroimmunol Neuroinflamm Subsets: MEDLINE
    • Publication Information:
      Original Publication: Baltimore, MD : Wolters Kluwer Health/Lippincott Williams & Wilkins, [2014]-
    • Subject Terms:
      Disease Progression*; Biomarkers/*cerebrospinal fluid ; Demyelinating Diseases/*cerebrospinal fluid ; Demyelinating Diseases/*pathology ; Multiple Sclerosis/*cerebrospinal fluid ; Multiple Sclerosis/*pathology; Adult ; Cohort Studies ; Female ; Humans ; Immunoglobulin A/blood ; Immunoglobulin A/cerebrospinal fluid ; Immunoglobulin A/metabolism ; Immunoglobulin G/blood ; Immunoglobulin G/cerebrospinal fluid ; Immunoglobulin G/metabolism ; Immunoglobulin M/blood ; Immunoglobulin M/cerebrospinal fluid ; Immunoglobulin M/metabolism ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; Tumor Necrosis Factor Receptor Superfamily, Member 7/blood ; Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism
    • Abstract:
      Objective: To identify CSF parameters at diagnosis of clinically isolated syndrome (CIS) and MS that are associated with early inflammatory disease activity as measured by standardized cerebral MRI (cMRI).
      Methods: One hundred forty-nine patients with newly diagnosed CIS and MS were included in the retrospective study. cMRI at onset and after 12 months was analyzed for T2 and gadolinium-enhancing lesions. CSF was tested for oligoclonal bands and intrathecal synthesis of immunoglobulin G (IgG), A (IgA), and M (IgM) before initiation of disease-modifying therapy (DMT). In a subgroup of patients, CSF and serum samples were analyzed for sCD27, neurofilament light chain, and IgG subclasses 1 and 3. Association between CSF parameters and cMRI activity was investigated by univariable and multivariable regression analysis in all patients, DMT-treated patients, and untreated patients.
      Results: IgG index, sCD27 levels in CSF, and to a lesser extent IgM index were associated with the occurrence of new cMRI lesions. IgG index and sCD27 levels in CSF were highly correlated. In a multivariable analysis, IgG index and to a lesser extent IgM index together with DMT treatment status and gender were strongest predictors of future cMRI activity.
      Conclusions: CSF parameters such as IgG and IgM index are independently associated with future MRI activity and thus might be helpful to support early treatment decisions in patients newly diagnosed with CIS and MS.
    • References:
      Lancet. 2001 May 19;357(9268):1576-82. (PMID: 11377645)
      J Neuroimmunol. 2001 Dec 3;121(1-2):120-5. (PMID: 11730948)
      Neurology. 2004 Nov 9;63(9):1586-90. (PMID: 15534240)
      J Neuroimmunol. 1991 Dec;35(1-3):211-7. (PMID: 1659587)
      Neurology. 2007 Apr 24;68(17):1390-401. (PMID: 17452584)
      Neurology. 2008 Mar 25;70(13 Pt 2):1079-83. (PMID: 17881717)
      Mult Scler. 2008 Mar;14(2):183-7. (PMID: 17942517)
      Brain. 2008 Mar;131(Pt 3):808-17. (PMID: 18234696)
      J Neurol Sci. 2010 Jan 15;288(1-2):147-50. (PMID: 19828154)
      Mult Scler. 2012 May;18(5):587-91. (PMID: 21965422)
      Neuroimage. 2012 Feb 15;59(4):3774-83. (PMID: 22119648)
      Arch Neurol. 2012 Oct;69(10):1259-69. (PMID: 22751847)
      Mult Scler. 2013 Jul;19(8):1074-83. (PMID: 23234810)
      J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):909-14. (PMID: 23431079)
      J Neuroimmunol. 2013 Apr 15;257(1-2):76-81. (PMID: 23434160)
      Mult Scler. 2013 Sep;19(10):1310-9. (PMID: 23447359)
      Mult Scler. 2015 Jul;21(8):1013-24. (PMID: 25680984)
      J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9. (PMID: 25716934)
      Brain. 2015 Jul;138(Pt 7):1863-74. (PMID: 25902415)
      Mult Scler. 2016 May;22(6):770-81. (PMID: 26362893)
      Mult Scler. 2016 Oct;22(12):1550-1559. (PMID: 26754800)
      Eur J Neurol. 2016 May;23(5):898-905. (PMID: 26872061)
      Neurol Neuroimmunol Neuroinflamm. 2016 Apr 20;3(3):e219. (PMID: 27144214)
      Neurology. 2016 Sep 13;87(11):1076-84. (PMID: 27521440)
      JAMA Neurol. 2017 Mar 1;74(3):286-292. (PMID: 28055081)
      Neurology. 2017 Feb 28;88(9):826-831. (PMID: 28148632)
      Eur J Neurol. 2017 May;24(5):703-712. (PMID: 28261960)
      Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. (PMID: 29209636)
      Neurol Neuroimmunol Neuroinflamm. 2018 Jan 22;5(2):e435. (PMID: 29435472)
      Mult Scler. 2019 Apr;25(5):678-686. (PMID: 29542376)
      Ann Neurol. 2018 May;83(5):1032-1036. (PMID: 29665046)
      Mult Scler. 2018 Nov;24(13):1715-1724. (PMID: 30019626)
      Front Immunol. 2018 Jul 13;9:1590. (PMID: 30057580)
      Mult Scler. 2018 Aug 16;:1352458518794308. (PMID: 30113249)
      Clin Chim Acta. 1987 Mar 30;163(3):319-28. (PMID: 3581475)
    • Accession Number:
      0 (Biomarkers)
      0 (Immunoglobulin A)
      0 (Immunoglobulin G)
      0 (Immunoglobulin M)
      0 (Tumor Necrosis Factor Receptor Superfamily, Member 7)
    • Publication Date:
      Date Created: 20190730 Date Completed: 20200930 Latest Revision: 20200930
    • Publication Date:
      20240628
    • Accession Number:
      PMC6624100
    • Accession Number:
      10.1212/NXI.0000000000000573
    • Accession Number:
      31355309